BobDoleYahoo Saturday, 08/12/17 02:34:26 PM Re: None Post # of 1804426 OXIS (potential 1,000-5,000% bagger) BREAKING OUT! Here's my DD on the company and its new leaders: The OXIS story reminds of me Puma Biotechnology (ticker: PBYI). The merger of OXIS "acquiring" GT Pharma is similar to a reverse merger, which the opposite actually happens (where a private company, in this case GT Pharma, takes over a publicly traded company, OXIS, to bypass the lengthy process of going public and basically speed up the process of starting the business). Since the CEO of GT Pharma is actually going to become the CEO of OXIS, I consider this technically a reverse merger. This new CEO actually has an excellent track record of being successful at Chase Pharmaceuticals and selling it off for a good profit to Allergan. The important thing is she is trustworthy to get OXIS going in the right direction. A company may have super-duper products in the pipeline but if the company has a poor leader, the company is going down the drain. I have to give props to the former CEO of OXIS, Anthony J. Cataldo, who I’m sure realized marching forward with OXIS was way over his head and found the perfect person to lead OXIS going forward. He could have remained CEO, but he didn’t. As for OXIS reminding me of PBYI, the founder of Puma Biotechnology (Alan Auerbach) first started a biotech company called Cougar Biotechnology. He developed Cougar successfully to the point where he sold it off to Johnson and Johnson for $1 billion. Here is where the OXIS story (or more specifically, the Dr. Clarence-Smith story) reminds me of the Alan Auerbach story. Alan Auerbach then started off another company, called Puma Biotechnology (what can you say? The guy loves felines…). According to Puma’s history (link below), it states: “On October 4, 2011, Puma completed a reverse merger with Innovative Acquisitions Corp., a publicly reporting "shell" company with no specific business plan or purpose. As a result of the merger, Puma became a wholly owned subsidiary of Innovative Acquisitions. The merged company changed its name to Puma Biotechnology and adopted Puma’s business plan. The company’s common stock began trading on April 20, 2012.” So in order for Alan to speed up the process of going public, he basically takes over an existing publicly trading company that was going nowhere. He then got it to the point where when good Phase 3 results were obtaining, the stock went from $58.99 to $200.68 overnight. It continues to climb to $270+ (or like 2,000%+ returns) at its peak. Sure, PBYI is trading at $78 now, but other than a few months when the trading first began, not at any other point in its history did the stock trade LOWER than its initial starting of $13. The point is OXIS is in a very, very promising position with previously successful Dr. Clarence-Smith as CEO and previously successful Pfizer CMO (whom I think is Joseph M. Feczko). It’s the “former CMO of Pfizer” so the current CMO of Pfizer can’t be a former CMO if they’re still the current one, right? The other former CMOs must be like super old. Logically that only leaves the prior CMO of Pfizer, who holds the correct titles noted in the news release 2 months ago, Joseph M. Feczko. When you have these kinds of successful leaders on board, great things happen. These types of successful individuals would not agree to join OXIS unless they themselves saw greater things on the horizon. http://pumabiotechnology.com/ir_faqs.html <-- OXIS merger with GT Pharma reminds me of reverse merge between Puma Biotechnology and the "shell" holding publicly traded company. https://www.linkedin.com/in/kathleen-clarence-smith-b2232779 <-- New CEO https://relationshipscience.com/joseph-m-feczko-p3193689 <-- New CMO? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360883/ <-- Phase 1 The sad thing is I told my brother I could read charts and told him to get in 15 MINUTES before Friday's breakout. He didn't. He just watched in awe, regretting, when the breakout started.